The improved anticancer effects of Bortezomib-loaded hollow mesoporous silica nanospheres on lymphoma development

As the first clinical proteasome inhibitor, Bortezomib (BTZ) has been reported to improve the outcome of lymphoma. However, due to the unstable property, low bioavailability, and hydrophobic properties of BTZ, it is needed to develop effective drug delivery systems to deliver BTZ into targeted cells...

Descripción completa

Detalles Bibliográficos
Autores principales: Shen, Jie, Wang, Ruihuan, Wang, Qing, Zhang, Minjuan, Liu, Chunyan, Tao, Zhenxia, Su, Guohong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals 2020
Materias:
Research Paper
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835069/
https://www.ncbi.nlm.nih.gov/pubmed/33290262
http://dx.doi.org/10.18632/aging.202146

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7835069/
https://www.ncbi.nlm.nih.gov/pubmed/33290262
http://dx.doi.org/10.18632/aging.202146

Ejemplares similares